Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease-Reference-Cited by-同舟云学术

Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease

Published:2013-07-25 Issue:3 Volume:91 Page:209-218
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:Eur J Haematol

Author:

Hoyos Montserrat,Nomdedeu Josep F.¹,Esteve Jordi¹,Duarte Rafael¹,Ribera Josep M.¹,Llorente Andreu¹,Escoda Lourdes¹,Bueno Javier¹,Tormo Mar¹,Gallardo David¹,de Llano Maria Paz Queipo¹,Martí Josep M.¹,Aventín Anna¹,Mangues Ramón²,Brunet Salut¹,Sierra Jorge

Affiliation:

1. Spanish CETLAM Group Hospital de la Santa Creu i Sant Pau; Universitat Autònoma de Barcelona Spanish Cancer Network (RTICC); Institut d'Investigació Biomèdica Sant Pau; Barcelona; Spain

2. Networking Research Center on Bioengineering Biomaterials and Nanomedicine (CIBER-BBN MICINN ISCIII); Barcelona; Spain

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ejh.12130/fullpdf

Reference31 articles.

1. Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): results from CALGB 8461;Byrd;J Clin Oncol,2004

2. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered;Byrd;J Clin Oncol,1999

3. Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?;Dombret;Curr Opin Hematol,2009

4. Core binding factor genes and human leukemia;Hart;Haematologica,2002

5. The World Health Organization (WHO) classification of the myeloid neoplasms;Vardiman;Blood,2002

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RUNX1::ETO and CBFβ::MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core‐binding factor‐acute myeloid leukaemia;British Journal of Haematology;2024-05-27

2. Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study;Annals of Hematology;2024-01-26

3. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment;Blood Reviews;2023-11

4. RUNX1-ETO and CBFβ-MYH11 converge on aberrant activation of BCAT1 to confer a therapeutic vulnerability in core binding factor-acute myeloid leukemia;2023-07-05

5. Minimal residual disease in acute leukemia based on the insight of molecular genetics monitoring;International Journal of ADVANCED AND APPLIED SCIENCES;2023-05